This article from Forbes reports on a new venture capital fund started by three former executives of Millennium Pharmaceuticals: Mark Levin, Kevin Starr, and Bob Tepper. They just raised $378 million for what they're calling Third Rock Ventures. According to the article, the fund will be closely managing startup companies, and will "only look at a few biotechs, each getting a few tens of millions of dollars."

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.